Pulmonary Fibrosis News and Research

RSS

Researchers identify stem cells responsible for lung regeneration

Guided by insights into how mice recover after H1N1 flu, researchers at Harvard Medical School and Brigham and Women's Hospital, together with researchers at A*STAR of Singapore, have cloned three distinct stem cells from the human airways and demonstrated that one of these cells can form into the lung's alveoli air sac tissue.

28 Oct 2011

Blood biomarker panel can predict survival in IPF patients

A panel of blood proteins can predict which patients with the progressive lung disease idiopathic pulmonary fibrosis (IPF) are likely to live at least five years or to die within two years, say researchers at the University of Pittsburgh School of Medicine and Centocor R&D.

27 Oct 2011

NIH stops triple-drug therapy clinical trial for idiopathic pulmonary fibrosis

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, has stopped one arm of a three arm multi-center, clinical trial studying treatments for the lung-scarring disease idiopathic pulmonary fibrosis (IPF) for safety concerns.

22 Oct 2011

Coughing may signal trouble for patients with idiopathic pulmonary fibrosis

A new analysis has found that coughing may signal trouble for patients with the lung-scarring disease known as idiopathic pulmonary fibrosis. The study, published in the journal Respirology, found that patients with the condition who also cough are more likely to develop advanced forms of the disease that may be life threatening.

19 Oct 2011

PFF establishes Research Fund to Cure Pulmonary Fibrosis

The Pulmonary Fibrosis Foundation (PFF) announced today that it has established the PFF Research Fund to Cure Pulmonary Fibrosis, a fund created to support research that will assist in the development of successful therapies for pulmonary fibrosis.

18 Oct 2011

Simmons Center to evaluate CGEN-25009 for treatment of idiopathic pulmonary fibrosis

Compugen Ltd. and the Pulmonary Fibrosis Foundation announced today that the Pulmonary Fibrosis Foundation will provide a grant to scientists at the University of Pittsburgh Dorothy P. and Richard P.

13 Oct 2011

InterMune reports new data from Esbriet clinical trial on IPF

InterMune, Inc. today reported that new data was presented at the European Respiratory Society (ERS) Annual Congress supporting the longer-term safety and tolerability of Esbriet(pirfenidone) in patients with idiopathic pulmonary fibrosis (IPF), a devastating lung disease.

26 Sep 2011

Bortezomib drug may also treat pulmonary fibrosis or scleroderma

A drug used to treat cancer may also be effective in diseases that cause scarring of the internal organs or skin, such as pulmonary fibrosis or scleroderma.

23 Sep 2011

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Boehringer Ingelheim's investigational tyrosine kinase inhibitor (TKI) BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to phase II clinical trial results published today online in the New England Journal of Medicine.

22 Sep 2011

InterMune to launch Esbriet for German patients with IPF

InterMune, Inc. today announced that Esbriet will be offered to patients in Germany beginning September 15, 2011. This will mark the first time Esbriet will be commercially available in Europe since it was approved by the European Commission in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a devastating and fatal lung disease.

12 Sep 2011

Bristol-Myers Squibb acquires Amira Pharmaceuticals

Bristol-Myers Squibb Company announced today that it has completed its previously announced acquisition of privately held Amira Pharmaceuticals, Inc., a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.

9 Sep 2011

Amniotic fluid-derived stem cells show promise against lung disease

Two papers published in the current issue of Cell Transplantation, highlight the rich source of stem cells in human amniotic fluid that can be isolated and transplanted for therapeutic purposes.

25 Aug 2011

Double-lung transplant survivor stays busy since retirement

Fewer than half of lung transplant patients survive for five years. But nearly 14 years after receiving a double-lung transplant at Loyola University Medical Center, Damian Neuberger's lungs continue to function normally. He breathes easily while walking four or five miles a day.

3 Aug 2011

Celgene reports second quarter total revenue of $1.18 billion

Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69.

28 Jul 2011

Bristol-Myers Squibb signs definitive agreement to acquire Amira Pharmaceuticals

Bristol-Myers Squibb Company and Amira Pharmaceuticals, Inc., announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Amira Pharmaceuticals, a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.

22 Jul 2011

Gastroespophageal reflux treatment might improve survival in patients with IPF

Patients with idiopathic pulmonary fibrosis (IPF) who report treatment for gastroespophageal reflux (GER) appear to have longer survival than IPF patients who are not treated for GERD, according to a new study from the University of California, San Francisco.

20 Jul 2011

Short telomeres may increase risk of emphysema

Telomeres, the body's own cellular clocks, may be a crucial factor underlying the development of emphysema, according to research from Johns Hopkins University.

15 Jul 2011

U.S. Senators introduce Pulmonary Fibrosis Research Enhancement Act

The Coalition for Pulmonary Fibrosis (CPF) announced today the Pulmonary Fibrosis Research Enhancement Act has been introduced in the Senate by Senators Chris Coons and Mike Crapo in the U.S. House of Representatives by Rep. Erik Paulsen and Rep. Tammy Baldwin.

13 Jul 2011

AJMS summarizes developments related to idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a common and severe lung disease of unknown cause and with no proven therapies. But researchers are pushing forward in investigating new clues to the development and effective treatment of IPF, according to a special symposium presented in The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation (SSCI).

8 Jul 2011

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

InterMune today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis.

8 Jul 2011